Fagron N.V. : M&A back on the agenda after COVID hiatus
>FY21 recap – slightly ahead of consensus - As guided, Fagron’s FY21 REBITDA landed at the lower end of the € 118-124m range (€ 118.3m), just ahead of consensus (<1%). Latin America was exceptionally strong (with 21.7%, on par with EMEA and its highest margin on record). North America was a tad soft, but saw a strong acceleration in 4Q21. Cash flow was somewhat impacted by strategic inventory build-up, but remained strong. Fagron guides for strong margin development ...Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.